The PCSK9 monoclonal antibody evolocumab (Repatha, Repatha Repatha Amgen) was well tolerated and effectively lowered LDL cholesterol by 38% compared with placebo in a randomized controlled trial in ...

Evolocumab, one of the new targeted PCSK9 inhibitor drugs that has been shown to dramatically lower levels of low-density lipoprotein (LDL), or “bad” cholesterol, also significantly lowers the risk of ...

Results from higher-risk subgroups could help clinicians target this cholesterol-fighting therapy to patients who most need it, authors of one abstract say. From the start, the debate about the ...

(HealthDay News) — Evolocumab shows promise for patients with heterozygous or homozygous familial hypercholesterolemia, according to two studies published online October 1 in The Lancet. Frederick J.

Please provide your email address to receive an email when new articles are posted on . “We designed the EBBINGHAUS study ... to assess the following hypothesis: [Did] the addition of evolocumab to ...

The monoclonal antibody evolocumab produced highly significant reductions in low-density lipoprotein cholesterol, the "bad cholesterol," as an add-on to statins in all treatment groups, according to ...

Review the side-effects of Evolocumab as documented in medical literature. The term "side effects" refers to unintended effects that can occur as a result of taking the medication. In majority of the ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Amgen announced that evolocumab met its co-primary ...

The addition of the PCSK9 inhibitor evolocumab (Repatha) to maximally tolerated statin therapy in patients with evidence of coronary artery disease significantly modifies atheroma volume as assessed ...

The PCSK9 inhibitor evolocumab (Repatha, Amgen) is far too expensive to make economic sense for the healthcare system and private payers, according to the results of yet another cost-effectiveness ...

Results from 3 phase 3 studies unveiled Saturday showed that investigational treatment for hyperlipidemia, evolocumab, significantly lowered low-density lipoprotein (LDL) cholesterol, that the results ...

THOUSAND OAKS, CA — Treating statin-intolerant patients with evolocumab (Amgen, Thousand Oaks, CA) significantly lowers LDL-cholesterol levels, according to the top-line results of the GAUSS-2 study ...